AnaptysBio
About AnaptysBio
AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The firm’s product pipeline includes Rosnilimab, ANB033, ANB101, Jemperli, and Imsidolimab. It operates through the Biopharma and Royalty Management segments. The Biopharma segment focuses on the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases. The Royalty Management segment manages the financial collaboration for Jemperli with GSK and for imsidolimab with Vanda. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
- Founded
- 2005
- CEO
- Mr. Daniel R. Faga
- Employees
- 104
- Headquarters
- San Diego, California, United States of America
- Fiscal year end
- 12-31
- Website
- anaptysbio.com
Company profile
- Exchange
- US
- Symbol
- ANAB
- Market-cap rank
- #3010
- Listing date
- 2017-01-26
- Market cap
- 1.39B
- Float cap
- 948.03M
- Shares out
- 29.73M
- Float shares
- 20.33M
Sectors & themes
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
AnaptysBio discussion 0 comments